

PRESS RELEASE

15 November 2022 10:00:00 CET

Senzime's investor event: Focus on growth, new clinical guidelines and updated financial outlook

Uppsala, November 15, 2022. Senzime AB (publ) will give an update at today's investor event on the strategy following the acquisition of Respiratory Motion (RMI), present the growth opportunities in the market given the new US and European clinical guidelines supporting Senzime's solutions, and provide an updated financial outlook.

Highlights that Senzime will present at today's digital investor event starting at 13:00 CET include:

- Senzime is on a mission to build a global leader within patient monitoring to eliminate anesthesia- and respiratory-related complications. There is a technology shift in the market supporting new innovative products.
- New clinical guidelines were recently approved in the US recommending Senzime's type of technology for patient monitoring. Senzime is well-positioned to gain market share and continue to drive the technology shift in neuromuscular monitoring to reduce complications, improve patient health and save healthcare cost.
- The recent acquisition of RMI and its monitoring solution ExSpiron has strengthened the product portfolio and expanded the market opportunity significantly. Focus is to continue to roll-out the products in key markets.
- The strategic collaboration with US company Masimo creates further market opportunities, expands reach, and gives more patients access to Senzime's monitoring solutions. The first joint solutions are expected to reach the market in the beginning of 2024.

Financial outlook:

- Net sales estimated to reach 275-325 MSEK by 2025, and long-term EBITDA margin estimated to exceed 40 percent. Senzime shall reach a market share of at least 10 percent in its active market segments.

"Senzime is in an exciting position with an innovative product portfolio supported by new clinical guidelines. We are well-positioned to continue our journey to build a leading position within our segments, drive growth and long-term profitability", says Pia Renaudin, CEO Senzime.

At today's investor event, Pia Renaudin, CEO, will together with Kay Krüger (Business manager of ExSpiron products) and Sorin J. Brull (Professor, board member of Senzime AB and the innovator of TetraGraph) present company strategy, growth opportunities, new clinical guidelines, and long-term financial targets.

The presentations will be held in English, followed by a Q&A session. Attendees will be able to submit questions via the webcast.

Date and time

Tuesday November 15, 2022, at 13:00-15:00 CET.

Link:

The webcast can be followed live via the link: [Investor event webcast](#)

After the event, there will be a recording available at senzime.com.

For further information, please contact:

Pia Renaudin, CEO of Senszime AB

Phone: +46 (0) 70-813 34 17, email: pia.renaudin@senzime.com

About Senszime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senszime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpirom® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.

This information is information that Senszime is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-11-15 10:00 CET.

Attachments

[Senzime's investor event: Focus on growth, new clinical guidelines and updated financial outlook](#)